Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced

Trial Details

NCT ID
NCT07413809
Phase
PHASE3
Sponsor
The Affiliated People's Hospital of Ningbo University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Fosaprepitant
  • Tropisetron
  • Olanzapine
  • Dexamethasone
Locations (sample)
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation;
  • Preconditioning regimen consists of melphalan at a dose of 200 mg/m²;
  • ECOG performance status score of 0 to 2;
  • Age \>18 years and \<65 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →